InMed Pharmaceuticals (INM) Gross Profit (2021 - 2025)
Historic Gross Profit for InMed Pharmaceuticals (INM) over the last 5 years, with Q4 2025 value amounting to $184194.0.
- InMed Pharmaceuticals' Gross Profit fell 6003.55% to $184194.0 in Q4 2025 from the same period last year, while for Dec 2025 it was $1.3 million, marking a year-over-year decrease of 2165.14%. This contributed to the annual value of $1.7 million for FY2025, which is 5501.55% up from last year.
- According to the latest figures from Q4 2025, InMed Pharmaceuticals' Gross Profit is $184194.0, which was down 6003.55% from $403159.0 recorded in Q3 2025.
- InMed Pharmaceuticals' Gross Profit's 5-year high stood at $1.6 million during Q2 2023, with a 5-year trough of -$491018.0 in Q3 2022.
- Moreover, its 5-year median value for Gross Profit was $249714.0 (2022), whereas its average is $314202.0.
- Data for InMed Pharmaceuticals' Gross Profit shows a peak YoY increase of 222281.8% (in 2024) and a maximum YoY decrease of 7032.11% (in 2024) over the last 5 years.
- Quarter analysis of 5 years shows InMed Pharmaceuticals' Gross Profit stood at $111555.0 in 2021, then increased by 17.58% to $131163.0 in 2022, then surged by 147.13% to $324142.0 in 2023, then soared by 42.19% to $460894.0 in 2024, then plummeted by 60.04% to $184194.0 in 2025.
- Its last three reported values are $184194.0 in Q4 2025, $403159.0 for Q3 2025, and $576654.0 during Q2 2025.